Escitalopram and Language Intervention for Subacute Aphasia (ELISA)

Who is this study for? Patients with Aphasia, Stroke
What treatments are being studied? Computer-Delivered Naming Treatment
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Behavioral, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

In this project, the investigators will investigate the effects of a selective serotonin reuptake inhibitor (SSRI), escitalopram, on augmenting language therapy effectiveness, as measured by naming untrained pictures and describing pictures, in individuals with aphasia in the acute and subacute post stroke period (i.e., within three months post stroke).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Participants must have sustained an acute ischemic left hemisphere stroke.

• Participants must be fluent speakers of English by self-report.

• Participants must be capable of giving informed consent or indicating a legally authorized representative to provide informed consent.

• Participants must be age 18 or older.

• Participants must be within 5 days of onset of stroke.

• Participants must be pre-morbidly right-handed by self-report.

• Participants must have an aphasia diagnosis as confirmed by the Western Aphasia Battery-Revised (Aphasia Quotient \< 93.8).

Locations
United States
Maryland
Johns Hopkins School of Medicine
RECRUITING
Baltimore
South Carolina
Medical University of South Carolina
RECRUITING
Charleston
University of South Carolina
RECRUITING
Columbia
Contact Information
Primary
Argye Hillis-Trupe, MD
argye@jhmi.edu
(410) 614-2381
Backup
Melissa D Stockbridge, PhD
md.stockbridge@jhmi.edu
Time Frame
Start Date: 2021-07-18
Estimated Completion Date: 2027-01-18
Participants
Target number of participants: 88
Treatments
Experimental: Naming Treatment + Escitalopram
10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
Placebo_comparator: Naming Treatment + Placebo
10 mg placebo daily for three months
Related Therapeutic Areas
Sponsors
Collaborators: Medical University of South Carolina, National Institute on Deafness and Other Communication Disorders (NIDCD), University of California, Irvine, University of South Carolina
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov